You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies

    SBC: EXAVIR THERAPEUTICS INC.            Topic: NIAID

    PROJECT SUMMARY While there are now successful treatment regimens and prevention strategies for people living with HIV/AIDS, the HIV pandemic remains a public health crisis in the United States and worldwide, with nearly 40,000 new infections each year in the US alone. To prevent the spread of HIV in vulnerable populations, the US Preventive Services Task Force has recommended HIV pre-exposure pro ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Preclinical evaluation of an otoprotectant TT002

    SBC: TING THERAPEUTICS LLC            Topic: NIDCD

    Project Summary Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However, cisplatin therapy causes hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection from cisplatin-induced hearing loss (CIHL). Most candid ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  3. CDK2 inhibitors for protecting hearing loss

    SBC: TING THERAPEUTICS LLC            Topic: NIDCD

    CDK2 inhibitors for protecting hearing loss Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However cisplatin anticancer therapy causes high frequency hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection fr ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  4. ProGel Technology for Better Management of Osteoarthritis Pain

    SBC: ENSIGN PHARMACEUTICAL, INC.            Topic: NIDA

    ABSTRACTAs one of the largest opioid consuming countries in the world, the prevalence of opioid use disorder (OUD) during 2017 is over 5 million in the U.S. alone. The significant increase of opioids use disorder (OUD) cases during the last 2 decades may be partially attributed to our overreliance on the prescription of the opioids for the management of non-cancer chronic pain, such as osteoarthri ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Seromic Mucin Signature for the Early Diagnosis of Pancreatic Cancer

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 102

    ABSTRACT Pancreatic cancerPCis an extremely aggressive malignancy with one of the worst prognoses of all cancersWith marked resistance to chemoand radiotherapiessurgery is the only curative optionIn patients with localized diseasecomplete surgical resection provides five year survival rate ofHoweverandgtof patients are diagnosed with unresectable primary tumors and or distant metastasisThe major c ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. A Prognostic Blood Test to Monitor Pancreatic Cancer Treatment by MiRNA Profiling

    SBC: VAJRA INSTRUMENTS, INC.            Topic: 102

    Pancreatic ductal adenocarcinomaPDAChas ayear survival rate of less thanThe success in developing therapies for other cancers over the last two decades has not improved the dismal overall survivalOSrate for PDACIt is now becoming increasingly apparent that personalized medicine based on the genetics of a tumor will be essential for developing a treatment strategyThusthere is an urgent need to deve ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. MUC4/16 assay for the early diagnosis and management of benign and malignant pancreatic diseases

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 300

    Abstract The goal of this Fast track application is to develop a non invasive diagnostic testbased on MUCand MUCmucinsthat can serve as an adjunct to cytological analysis of fine needle aspiratesFNAsfor accurate prediction of malignancy in patients with cystic pancreatic lesionsDue to asymptomatic nature and lack of methods for early detectionandgtof pancreatic cancerPCpatients present with an unr ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Next Generation Western for high-throughput and high-content protein analysis

    SBC: LI-COR, Inc.            Topic: 400

    Abstract The identification and quantification of specific proteins in complex samples are critical processes in discoveringunderstandingand ultimately addressingthe underlying nature of human health and diseaseThe western blot is a fundamental method used for these processes due to the sensitivity and specificity enabled by combining protein sizing with immuno detectionDespite being widelyusedthe ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. IMPROVING THE TREATMENT OF CONTAMINATED AQUIFERS BYDEVELOPING DIRECT-PUSH OXIDANT CANDLES WITH PNEUMATIC CIRCULATORS

    SBC: AirLIft Environmental LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Clean water is one of the most basic societal needs in the world Few situations incite more public outcry than when a community learns that their drinking water has been tainted Two of the biggest threats to groundwater quality in the U S are contamination from either chlorinated solvents or petroleum Left unattended the size and scope of the problems asso ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government